Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with L
-
Plus Therapeutics Announces New Employment Inducement Grants
-
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
-
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
-
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
-
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
-
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
-
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breas
-
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
-
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply